Lumicell, a privately held company focused on developing innovative fluorescence-guided imaging technologies for cancerous tissue detection during surgery, is pleased to announce the appointment of Jim Alecxih to its Board of Directors.
HealthTech Insights: MolecuLight Secures $27.5 Million From Hayfin, a Leading Healthcare Institutional Investor
The Lumicell Board has appointed Mr. Jim Alecxih as a new independent director. Currently serving as Chief Executive Officer of DH Medical, Alecxih leads a team focused on advancements in imaging, video transmission, and signal processing technologies. He previously held executive leadership roles at other market-leading companies, including Intuitive Surgical, where he spearheaded exponential revenue growth of robotic-assisted surgical systems.
HealthTech Insights: Candid Therapeutics Enters into Agreement with WuXi Biologics on Trispecific T-cell Engager
“I’m honored to join Lumicell’s Board of Directors at such a pivotal moment in the company’s history.”
“We’re excited to welcome Jim to our Board of Directors. His extensive commercial and operational experience, along with a proven track record of success, will be invaluable to Lumicell,” said Howard Hechler, Chief Executive Officer of Lumicell. “Jim’s deep experience in the healthcare industry and diagnostic imaging aligns seamlessly with Lumicell’s mission to advance cancer detection across the continuum of solid tumors and improve surgical outcomes.”
HealthTech Insights: Nemours Children’s Health and State of Delaware to Launch First-of-its-Kind Payment Model for Children’s Health
“I’m honored to join Lumicell’s Board of Directors at such a pivotal moment in the company’s history, as it is initiating its U.S. commercial launch. I look forward to contributing to the continued development and research of its platform technology,” said Alecxih. “Lumicell’s innovative fluorescence-guided imaging technology fills critical gaps in cancer care, offering the ability to detect cancer that would otherwise remain undetected.”
To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com
Source – prnewswire
